diabetes drugs
Coverage of diabetes drugs in the Nexus archive.
- Chinese biotech giant Wuxi AppTec sees first-half earnings surge amid US scrutiny
Wuxi AppTec, Asia’s largest contract pharmaceutical research provider, reported a 33.7% year-on-year increase in first-half net profit to 11.08 billion yuan, driven by strong demand for weight-loss and diabetes drugs and growth in its US business. The company’s earnings exceeded Bloomberg analysts’ expectations.
- Chinese biotech giant Wuxi AppTec sees first-half earnings surge amid US scrutiny
Wuxi AppTec, Asia’s largest contract pharmaceutical research provider, reported a 33.7% year-on-year increase in first-half net profit to 11.08 billion yuan, driven by strong demand for weight-loss and diabetes drugs and growth in its US business. The results exceeded Bloomberg analysts' consensus estimates.
- GLP-1s appear to protect against cancer. Researchers are trying to figure out how
Recent studies suggest GLP-1s, weight loss and diabetes drugs, may prevent cancer and slow its progression. While weight loss is known to reduce cancer risks, GLP-1s might act on additional brain and metabolic pathways to achieve this effect.